Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Arcturus Therapeutics Holdings Inc ARCT.OQ reported a quarterly adjusted loss of 84 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of twelve analysts for the quarter was for a loss of 100 cents per share. Wall Street expected results to range from $-1.35 to -74 cents per share.
Revenue fell 89.5% to $2.96 million from a year ago; analysts expected $3.20 million.
Arcturus Therapeutics Holdings Inc's reported EPS for the quarter was a loss of 84 cents.
The company reported a quarterly loss of $23.79 million.
Arcturus Therapeutics Holdings Inc shares had fallen by 6.8% this quarter and gained 2.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 7.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $20.00, about 68.7% above its last closing price of $6.26
This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -1.00 | -0.84 | Beat |
Mar. 31 2026 | -1.09 | -0.95 | Beat |
Dec. 31 2025 | -0.71 | -1.03 | Missed |
Sep. 30 2025 | -0.82 | -0.49 | Beat |
Recent news on Arcturus Therapeutics Holdings
See all newsBrief: Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Arcturus Q2 revenue falls sharply on CSL Seqirus deal end
Brief: Arcturus Therapeutics Q2 Net Income USD -23.785 Million
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview